Novocure said its second-quarter revenue rose 16% year over year, beating analyst expectations. The company posted a second-quarter net loss of $15.7 million.
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$183.58 million
$172.44 million (6 Analysts)
Q2 Net Loss
$15.66 million
Q2 Gross Profit
$142.48 million
Q2 Operating Income
-$10.56 million
Q2 Pretax Loss
$12.45 million
Analyst coverage and price target
The current average analyst rating on the shares is buy, with 4 strong buy or buy ratings, 3 hold ratings and no sell or strong sell ratings.
The median 12-month price target for Novocure Ltd is $23.50, about 50.9% above its July 22 closing price of $15.57.
Drivers included active patient growth and one-time benefits
The company said the revenue increase was primarily driven by 18% global active patient growth across indications.
Revenue also reflected contributions from new product launches, including Optune Pax and Optune Lua. Novocure said Optune Pax received CE Mark and launched in Germany.
Second-quarter revenue included $2.8 million in one-time benefits in the U.S., Germany and France.
2026 guidance raised on patient growth and launches
Novocure raised its 2026 revenue guidance to $710 million-$725 million from $690 million-$710 million. The company expects 2026 adjusted EBITDA of $0 million-$15 million, up from prior guidance of $(15) million-$0 million.
The guidance assumes mid-to-high single digit net revenue growth from Optune Gio.
NVCR•
